One to add to the list, FWIW. I haven't had time for more than a cursory glance, but they have a good chunk of change from the recent IPO -
May 16 /PRNewswire/ -- Genomic Solutions Inc. (Nasdaq: GNSL - news) is strengthening its leadership position in Proteomics through development of a new Center for Proteomics to be located at the Company's Ann Arbor, Michigan headquarters. This new facility will support proteomics R&D as well as contract research and technical services for Genomic Solutions' proteomics customers. The Center will be equipped with multiple units of the Company's automated Investigator(TM) Proteomics System, as well as next generation products currently in development. These capabilities will enable industrial-scale protein identification, characterization and expression analysis.
The Company's current Chelmsford, MA proteomics facility will also be relocated to Ann Arbor. The Company plans to take a one time restructuring charge of approximately $600,000 during the second quarter associated with closing the Chelmsford facility and anticipates favorable financial, operating and strategic results from the consolidation of its proteomics operations in Ann Arbor.
Michael Pisano, Ph.D, most recently Head, Protein Sciences/US at Aventis Pharmaceuticals in Collegeville, PA, has joined Genomic Solutions as the Company's Vice President of Proteomics R&D. Rick Edmondson, Ph.D, also from Aventis, will manage the company's Mass Spectrometry efforts. ``As a scientist and a manager, Dr. Pisano is ideally suited to lead our team in the continued development of essential tools our customers need to further their proteomic research,'' said Chris Ethier, Vice President of the Proteomic Business Unit. Plans are already underway to recruit additional scientists, engineers and bioinformatics specialists for the Center.
``With its business focus on functional genomics and proteomics, Genomic Solutions is uniquely positioned to profit from the convergence of these rapidly growing markets,'' said Jeff Williams President and CEO. ``This investment in the Center for Proteomics reinforces our commitment to remain a leader in providing systems solutions for drug discovery.''
Genomic Solutions Inc. designs, develops, manufactures, markets and sells instruments, software, consumables and services used to determine the activity level of genes and to isolate, identify and characterize proteins. The Company's products and systems enable researchers to perform complex, high volume experiments at a lower cost and in less time that traditional techniques. As a result, Genomic Solutions products and systems facilitate more rapid and less expensive drug discovery.
For more information, contact us at info@genomicsolutions.com or visit our website, genomicsolutions.com. |
